11/24/2020 7:09:49 AM
Alnylam Announces Innovative Value-Based Agreement Framework For OXLUMO
11/24/2020 7:06:47 AM
Alnylam: FDA Approves OXLUMO For PH1 To Lower Urinary Oxalate Levels In Pediatric, Adult Patients
11/19/2020 7:05:37 AM
Alnylam Pharma: European Commission Grants Marketing Authorization For OXLUMO For Primary Hyperoxaluria Type 1
11/13/2020 9:03:30 AM
Alnylam Announces Positive Interim Data From Ongoing Phase 1 Study Of ALN-AGT
11/5/2020 8:17:25 AM
Alnylam Pharmaceuticals Inc. (ALNY) Has Raised Its FY20 Revenue Estimate To $295 - $310 Mln From $280 - $300 Mln
11/5/2020 8:04:27 AM
Alnylam Pharma Q3 GAAP Loss Per Share $2.18; Non-GAAP Loss Per Share $1.58
10/22/2020 10:14:41 AM
Alnylam Presents Positive Results From Phase 3 Study In Pediatric Patients With Primary Hyperoxaluria Type 1
10/16/2020 6:03:42 AM
Alnylam Gets Positive CHMP Opinion For OXLUMO For Primary Hyperoxaluria Type 1 In All Age Groups
9/30/2020 7:07:08 AM
Alnylam Reports Positive Topline Results From ILLUMINATE-B Phase 3 Study Of Lumasiran
8/17/2020 7:34:16 AM
Blackstone And Alnylam Close $150 Mln R&D Financing To Advance RNAi Therapeutics For Cardiovascular Disease